SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:research.chalmers.se:c115fe02-5f82-4cd8-b278-f235f1cc60df"
 

Search: onr:"swepub:oai:research.chalmers.se:c115fe02-5f82-4cd8-b278-f235f1cc60df" > Lopinavir/ritonavir...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Andersson, Lars-Magnus,1968Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine (author)

Lopinavir/ritonavir, atazanavir/ritonavir, and efavirenz in antiretroviral-naïve HIV-1-infected individuals over 144 weeks: An open-label randomized controlled trial.

  • Article/chapterEnglish2013

Publisher, publication year, extent ...

  • 2013-01-07
  • Informa UK Limited,2013

Numbers

  • LIBRIS-ID:oai:research.chalmers.se:c115fe02-5f82-4cd8-b278-f235f1cc60df
  • https://doi.org/10.3109/00365548.2012.756985DOI
  • https://research.chalmers.se/publication/173827URI
  • https://lup.lub.lu.se/record/3921093URI
  • https://gup.ub.gu.se/publication/173827URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:127008159URI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Background: The objective of this study was to compare the efficacy of ritonavir boosted atazanavir versus ritonavir boosted lopinavir or efavirenz, all in combination with 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs), over 144 weeks in antiretroviral-naïve HIV-1-infected individuals. Methods: A prospective open-label randomized controlled trial was conducted at 29 sites in Sweden and Norway between April 2004 and December 2009. Patients were randomized to receive either efavirenz 600 mg once daily (EFV), or atazanavir 300 mg and ritonavir 100 mg once daily (AZV/r), or lopinavir 400 mg and ritonavir 100 mg twice daily (LPV/r). The primary endpoints were the proportion of patients with HIV-1 RNA 100,000 copies/ml at baseline had similar response rates in all arms. Conclusion: EFV was superior to LPV/r at week 48, but there were no significant differences between the 3 arms in the long-term (144 weeks) follow-up.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Vesterbacka, J.Karolinska Institutet (author)
  • Blaxhult, AndersKarolinska Institutet (author)
  • Flamholc, LeoLund University,Lunds universitet,Enheten för infektionssjukdomar,Forskargrupper vid Lunds universitet,Infectious Diseases Research Unit,Lund University Research Groups(Swepub:lu)inf-lfl (author)
  • Nilsson, Staffan,1956Gothenburg University,Göteborgs universitet,Institutionen för matematiska vetenskaper, matematisk statistik,Department of Mathematical Sciences, Mathematical Statistics(Swepub:gu)xnista (author)
  • Ormaasen, VidarOslo universitetssykehus,Oslo University Hospital (author)
  • Sonnerborg, A.Karolinska Institutet (author)
  • Gisslén, Magnus,1962Gothenburg University,Göteborgs universitet,Institutionen för biomedicin, avdelningen för infektionssjukdomar,Institute of Biomedicine, Department of Infectious Medicine(Swepub:gu)xgissm (author)
  • Göteborgs universitetInstitutionen för biomedicin, avdelningen för infektionssjukdomar (creator_code:org_t)

Related titles

  • In:Scandinavian Journal of Infectious Diseases: Informa UK Limited45:7, s. 543-5510036-55481651-1980

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view